company background image
LYS logo

Lysogene ENXTPA:LYS Stock Report

Last Price

€0.28

Market Cap

€4.9m

7D

0%

1Y

-59.5%

Updated

08 Jul, 2023

Data

Company Financials

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

LYS Stock Overview

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders.

LYS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Lysogene S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lysogene
Historical stock prices
Current Share Price€0.28
52 Week High€0.82
52 Week Low€0.23
Beta0.91
1 Month Change0%
3 Month Changen/a
1 Year Change-59.49%
3 Year Change-88.45%
5 Year Change-86.16%
Change since IPO-95.90%

Recent News & Updates

Recent updates

Breakeven On The Horizon For Lysogene S.A. (EPA:LYS)

May 05
Breakeven On The Horizon For Lysogene S.A. (EPA:LYS)

Lysogene (EPA:LYS) Shareholders Have Enjoyed A 5.9% Share Price Gain

Feb 17
Lysogene (EPA:LYS) Shareholders Have Enjoyed A 5.9% Share Price Gain

Shareholder Returns

LYSFR BiotechsFR Market
7D0%1.1%0.2%
1Y-59.5%-3.3%8.6%

Return vs Industry: LYS underperformed the French Biotechs industry which returned -21.8% over the past year.

Return vs Market: LYS underperformed the French Market which returned 17.5% over the past year.

Price Volatility

Is LYS's price volatile compared to industry and market?
LYS volatility
LYS Average Weekly Movementn/a
Biotechs Industry Average Movement5.8%
Market Average Movement4.3%
10% most volatile stocks in FR Market9.4%
10% least volatile stocks in FR Market2.2%

Stable Share Price: LYS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine LYS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200922Karen Pignet-Aiachhttps://www.lysogene.com

Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a research collaboration with the Yeda Research and Development Co Ltd.

Lysogene S.A. Fundamentals Summary

How do Lysogene's earnings and revenue compare to its market cap?
LYS fundamental statistics
Market cap€4.95m
Earnings (TTM)-€7.37m
Revenue (TTM)€12.77m

0.4x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LYS income statement (TTM)
Revenue€12.77m
Cost of Revenue€0
Gross Profit€12.77m
Other Expenses€20.14m
Earnings-€7.37m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin100.00%
Net Profit Margin-57.76%
Debt/Equity Ratio-402.9%

How did LYS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.